An immunohistochemical study of feline endometrial adenocarcinoma.

R. M. Gil da Costa,M. Santos,I. Amorim,C. Lopes,P. D. Pereira,A. Faustino

DOI: https://doi.org/10.1016/j.jcpa.2008.12.006

IF: 1.083

2009-05-01

Journal of Comparative Pathology

Abstract:

What problem does this paper attempt to address?

Evaluation of MicroRNA as Minimal Residual Disease in Leukemia: Diagnostic and Prognostic Approach: A Review

Bahareh Shateri Amiri,Neda Sabernia,Behdokht Abouali,Parya Amini,Hadi Rezaeeyan

DOI: https://doi.org/10.18502/ijph.v52i12.14315

Abstract:Various factors are effective in the development of minimal residual disease (MRD), one of which is MicroRNAs (miRNAs). miRNAs and their dysfunction in gene expression have influential role in the pathogenesis of leukemia. Nowadays, treatments that lead to the suppression or replacement of miRNAs have been developed. Focusing on the role of miRNAs in managing the treatment of leukemia, in this review article we have investigated the miRNAs and signaling pathways involved in the process of apoptosis and cell proliferation, as well as miRNAs with oncogenic function in malignant leukemia cells. Among the studied miRNAs, miR-99a, and miR-181a play an essential role in apoptosis, proliferation and oncogenesis via AKT, MAPK, RAS, and mTOR signaling pathways. miR-223 and miR-125a affect apoptosis and oncogenesis via Wnt/B-catenin, PTEN/PI3K, and STAT5/AKT/ERK/Src signaling pathways. miR-100 also affects both apoptosis and oncogenesis; it acts via IGF1 and mTOR signaling pathways.
Immobilization of human mesenchymal stem cells within RGD-grafted alginate microspheres and assessment of their angiogenic potential.

S. Bidarra,C. Barrias,M. Barbosa,R. Soares,P. Granja

DOI: https://doi.org/10.1021/bm100264a

2010-07-13

Biomacromolecules

Abstract:In this work, human mesenchymal stem cells (hMSC) immobilized in RGD-coupled alginate microspheres, with a binary composition of high and low molecular weight alginate, were investigated. Cells immobilized within RGD-alginate microspheres (during 21 days) showed metabolic activity, with an overall viability higher than 90%, short cell extensions, and, when induced, they were able to differentiate into the osteogenic lineage. In osteogenic conditions (comparing to basal conditions), immobilized cells presented alkaline phosphatase (ALP) activity and an upregulation of ALP, collagen type I, and Runx 2 expression. Moreover, mineralization was also detected in immobilized cells under osteogenic stimulus. In addition, it was demonstrated for the first time that MSCs immobilized in this 3D matrix were able to enhance the ability of neighboring endothelial cells to form tubelike structures. Overall, these findings represent a step forward in the development of injectable stem cell carriers for bone tissue engineering.
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification

Stavroula Syriopoulou,Christina-Nefeli Kontandreopoulou,Panagiotis T. Diamantopoulos,Dimitra Vlachopoulou,Christos Stafylidis,Panagiota Katsiampoura,Sevastianos Chatzidavid,Nefeli Giannakopoulou,Vassiliki Pappa,Ioannis Kotsianidis,Eleftheria Hatzimichael,Maria Dimou,Argiris Symeonidis,Panayiotis Panayiotidis,Nora-Athina Viniou,for the Hellenic MDS Study Group

DOI: https://doi.org/10.1080/10428194.2024.2412291

2024-10-10

Leukemia & Lymphoma

Abstract:MiRNAs have been identified as participants in leukemogenesis by controlling several cellular functions, such as differentiation, proliferation, and apoptosis. Their role in myelodysplastic neoplasms (MDS) pathogenesis is researched due to implementations in early identification, classification, and therapeutical options. IPSS-R, being the most widely used MDS classification, underestimates early biological events that can alter the disease's prognosis. The purpose of this study is to determine whether miRNA levels are aligned to MDS risk stratification groups and can therefore be used as diagnostic biomarkers. To evaluate miRNAs as possible biomarkers, we measured the levels of miR-181a-2-3p, miR-124-3p, miR-550a-3p, miR-155-5p, miR-151a-3p, and miR-125b-5p by a quantitative real-time PCR in bone marrow samples of 41 MDS patients. In conclusion, in myeloid malignancies, genomic characteristics may provide a wider apprehension of its clinical course and prognosis. MiRNAs constitute a possible diagnostic biomarker and therapeutic target, allowing intermediate-risk patients that express high levels of specific miRNAs to be re-classified and receive more advanced therapeutic agents. In our study, an association between high levels of miRNAs and worsening outcomes is established, supporting the need for further incorporation of molecular data into currently used classification systems.

oncology,hematology
Small Molecules, Big Effects: the Role of Micrornas in Regulation of Cardiomyocyte Death

Joanna Skommer,Indrajeetsinh Rana,Francine Z. Marques,Wenliang Zhu,Zhenhong Du,Fadi J. Charchar

DOI: https://doi.org/10.1038/cddis.2014.287

2014-01-01

Cell Death and Disease

Abstract:MicroRNAs (miRNAs) are a class of small non-coding RNAs involved in posttranscriptional regulation of gene expression, and exerting regulatory roles in plethora of biological processes. In recent years, miRNAs have received increased attention for their crucial role in health and disease, including in cardiovascular disease. This review summarizes the role of miRNAs in regulation of cardiac cell death/cell survival pathways, including apoptosis, autophagy and necrosis. It is envisaged that these miRNAs may explain the mechanisms behind the pathogenesis of many cardiac diseases, and, most importantly, may provide new avenues for therapeutic intervention that will limit cardiomyocyte cell death before it irreversibly affects cardiac function. Through an in-depth literature analysis coupled with integrative bioinformatics (pathway and synergy analysis), we dissect here the landscape of complex relationships between the apoptosis-regulating miRNAs in the context of cardiomyocyte cell death (including regulation of autophagy-apoptosis cross talk), and examine the gaps in our current understanding that will guide future investigations.
miRNA Profiles in Patients with Hematological Malignancy at Different Stages of the Disease: A Preliminary Study

Jood Hashem,Lujain Alkhalaileh,Hassan Abushukair,Mahmoud Ayesh

DOI: https://doi.org/10.3390/biomedicines12081924

IF: 4.757

2024-08-24

Biomedicines

Abstract:The dysregulation of miRNA expression has been shown to impact cellular physiology and tumorigenesis. Studies have reported several miRNA regulatory elements and pathways that play a significant role in the diagnosis, prognosis, and treatment of hematological malignancies. This is the first study to test the differential expression of miRNAs at crucial stages of the disease, specifically newly diagnosed, resistant to treatment, and remission. Circulating miRNAs extracted from the blood samples of 18 patients diagnosed with leukemia or lymphoma at different stages and 2 healthy controls were quantified by qPCR using a panel of 96 tumorigenic miRNAs. An enrichment analysis was performed to understand the mechanisms through which differential miRNA expression affects cellular and molecular functions. Significant upregulation of hsa-miR-1, hsa-miR-20a-5p, hsa-miR-23a-3p, hsa-miR-92b3p, and hsa-miR-196a-5p was detected among the different stages of leukemia and lymphoma. mir-1 and mir-196a-5p were upregulated in the remission stage of leukemia, while mir-20a-5p, mir-23a-3p, and mir-92b-3p were upregulated during the resistant stage of lymphoma. The enrichment analysis revealed these miRNAs' involvement in the RAS signaling pathway, TGF-β signaling, and apoptotic pathways, among others. This study highlights new biomarkers that could be used as potential targets for disease diagnosis, prognosis, and treatment, therefore enhancing personalized treatments and survival outcomes for patients.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis

Solmaz Shirjang,Behzad Mansoori,Samira Asghari,Pascal H G Duijf,Ali Mohammadi,Morten Gjerstorff,Behzad Baradaran

DOI: https://doi.org/10.1016/j.freeradbiomed.2019.05.017

2019-08-01

Abstract:To protect tissues and the organism from disease, potentially harmful cells are removed through programmed cell death processes, including apoptosis and necroptosis. These types of cell death are critically controlled by microRNAs (miRNAs). MiRNAs are short RNA molecules that target and inhibit expression of many cellular regulators, including those controlling programmed cell death via the intrinsic (Bcl-2 and Mcl-1), extrinsic (TRAIL and Fas), p53-and endoplasmic reticulum (ER) stress-induced apoptotic pathways, as well as the necroptosis cell death pathway. In this review, we discuss the current knowledge of apoptosis and necroptosis pathways and how these are impaired in cancer cells. We focus on how miRNAs disrupt apoptosis and necroptosis, thereby critically contributing to malignancy. Understanding which and how miRNAs and their targets affect cell death pathways could open up novel therapeutic opportunities for cancer patients. Indeed, restoration of pro-apoptotic tumor suppressor miRNAs (apoptomiRs) or inhibition of oncogenic miRNAs (oncomiRs) represent strategies that are currently being trialed or are already applied as miRNA-based cancer therapies. Therefore, better understanding the cancer type-specific expression of apoptomiRs and oncomiRs and their underlying mechanisms in cell death pathways will not only advance our knowledge, but also continue to provide new opportunities to treat cancer.
Integrated analysis on mRNA microarray and microRNA microarray to screen immune-related biomarkers and pathways in myelodysplastic syndrome

Chunyi Lyu,Kui Liu,Yuehua Jiang,Teng Wang,Yan Wang,Ruirong Xu

DOI: https://doi.org/10.1080/16078454.2021.1938429

IF: 2.264

2021-01-01

Hematology

Abstract:<span>Myelodysplastic syndrome (MDS) is a haematopoietic malignancy that is characterized by a heterogeneous clinical course and dysplastic maturation of blood lineages. Immune dysregulation has gained attention as one of the fundamental mechanisms responsible for the development of MDS. This study aimed to screen immune-related biomarkers and pathways in MDS.Differentially expressed mRNAs (DE-mRNAs) and differentially expressed microRNAs (DE-miRNAs) in different subtypes of MDS were sourced from the Gene Expression Omnibus (GEO) database. DE-mRNAs were intersected with immune-related gene sets to collect immune-related mRNAs, which were put into the Search Tool for the Retrieval of Interacting Genes (STRING) to construct protein–protein interaction (PPI) networks. Target mRNAs of DE-miRNAs were predicted using the miRDB database and intersected with screened immune-related mRNAs to construct miRNA-mRNA interaction networks. Topological analysis of constructed networks was applied to screen key molecules, which were assessed in independent datasets and previous literature. Enrichment analysis was applied to screen dysregulated pathways in MDS.Screened key mRNAs were mainly from the Toll-like receptor (TLR) family, including TLR2, TLR4, TLR7, and from the chemokine family, including C-X-C motif chemokine ligand 10 (CXCL10) and CC chemokine ligand 4 (CCL4). Cytokine-cytokine receptor interactions were among the major pathways in the enrichment analysis results. Hsa-miR-30b, hsa-miR-30e and hsa-miR-221 were validated as key miRNAs and modulate cytokine-cytokine receptor interactions by targeting immune-related mRNAs.Dysregulated cytokines reflect the immunization status in MDS. Immune-related miRNA-mRNA interactions not only provide a perspective to our understanding of immunologic derangement in the pathogenesis of MDS but also provide new therapeutic opportunities.</span>

hematology
How do humans process and recognize speech?

J. Allen

DOI: https://doi.org/10.1109/89.326615

1993-04-01

IEEE Transactions on Speech and Audio Processing

Abstract:Until the performance of automatic speech recognition (ASR) hardware surpasses human performance in accuracy and robustness, we stand to gain by understanding the basic principles behind human speech recognition (HSR). This problem was studied exhaustively at Bell Labs between the years of 1918 and 1950 by Harvey Fletcher and his colleagues. The motivation for these studies was to quantify the quality of speech sounds in the telephone plant to both improve speech intelligibility and preference. To do this he and his group studied the effects of filtering and noise on speech recognition accuracy for nonsense consonant-vowel-consonant (CVC) syllables, words, and sentences. Fletcher used the term "articulation" as the probability of correct recognition for nonsense sounds, and "intelligibility" as the probability of correction recognition for words (sounds having meaning). In 1919, Fletcher found a way to transform articulation data for filtered speech into an additive density function D(f) and found a formula that accurately predicts the average articulation. The area under D(S) is called the "articulation index." Fletcher then went on to find relationships between the recognition errors for the nonsense speech sounds, words, and sentences. This work has recently been reviewed and partially replicated by Boothroyd and by Bronkhorst, et al. (1980). Taken as a whole, these studies tell us a great deal about how humans process and recognize speech sounds. >
Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives

Alireza Mafi,Hamidreza Rismanchi,Yasaman Gholinezhad,Mohaddese Malek Mohammadi,Vahide Mousavi,Seyed Ali Hosseini,Yaser Eshaghi Milasi,Russel J Reiter,Behrooz Ghezelbash,Malihe Rezaee,Amirhossein Sheida,Fatemeh Zarepour,Zatollah Asemi,Mohammad Ali Mansournia,Hamed Mirzaei

DOI: https://doi.org/10.3389/fphar.2023.1224151

2023-08-14

Abstract:Leukaemia is a dangerous malignancy that causes thousands of deaths every year throughout the world. The rate of morbidity and mortality is significant despite many advancements in therapy strategies for affected individuals. Most antitumour medications used now in clinical oncology use apoptotic signalling pathways to induce cancer cell death. Accumulated data have shown a direct correlation between inducing apoptosis in cancer cells with higher tumour regression and survival. Until now, the efficacy of melatonin as a powerful antitumour agent has been firmly established. A change in melatonin concentrations has been reported in multiple tumours such as endometrial, hematopoietic, and breast cancers. Findings show that melatonin's anticancer properties, such as its prooxidation function and ability to promote apoptosis, indicate the possibility of utilizing this natural substance as a promising agent in innovative cancer therapy approaches. Melatonin stimulates cell apoptosis via the regulation of many apoptosis facilitators, including mitochondria, cytochrome c, Bcl-2, production of reactive oxygen species, and apoptosis receptors. This paper aimed to further assess the anticancer effects of melatonin through the apoptotic pathway, considering the role that cellular apoptosis plays in the pathogenesis of cancer. The effect of melatonin may mean that it is appropriate for use as an adjuvant, along with other therapeutic approaches such as radiotherapy and chemotherapy.
Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review

Mohammad Parsa-kondelaji,Maryam Musavi,Faezeh Barzegar,Neda Abbasian,Mehrdad Rostami,Mohammad R Seyedtaghia,Seyyed S Hashemi,Mahdiyeh Modi,Banafsheh Nikfar,Amir A Momtazi-Borojeni

DOI: https://doi.org/10.2217/bmm-2023-0575

2024-01-19

Biomarkers in Medicine

Abstract:Aim: The present systematic review aimed to explore miRNAs as a potential biomarker for early diagnosis of chronic myeloid leukemia (CML). Materials & methods: A systematic search was conducted in three electronic databases, including Web of Science, Scopus, and PubMed, to obtain relevant articles investigating the alteration of miRNA expression in patients with CML. Results: The authors found miRNAs whose expression changes are effective in the induction of CML disease. Among them, miR-21 and miR-155 were identified as the most common miRNAs with increased expression and miR-150 and miR-146 as the most common miRNAs with decreased expression. Conclusion: miRNAs can be used as an indicator for the early detection and treatment of CML phase.

medicine, research & experimental
An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (lncRNAs) in Myelodysplastic Syndromes

Xiaoli Zhao,Hua Yin,Nianyi Li,Yu Zhu,Wenyi Shen,Sixuan Qian,Guangsheng He,Jianyong Li,Xiaoqin Wang

DOI: https://doi.org/10.3389/fonc.2019.00200

2019-03-29

Abstract:Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis, defective differentiation of hematopoietic precursors, and expansion of the abnormal clones. The prevalence of MDS has raised great concerns worldwide, but its pathogenetic mechanisms remain elusive. To provide insights on novel biomarkers for the diagnosis and therapy of MDS, we performed high-throughput genome-wide mRNA expression profiling, DNA methylation analysis, and long non-coding RNAs (lncRNA) analysis on bone marrows from four MDS patients and four age-matched healthy controls. We identified 1,937 differentially expressed genes (DEGs), 515 methylated genes, and 214 lncRNA that showed statistically significant differences. As the most significant module-related DEGs, TCL1A, PTGS2, and MME were revealed to be enriched in regulation of cell differentiation and cell death pathways. In addition, the GeneGo pathway maps identified by top DEGs were shown to converge on cancer, immunoregulation, apoptosis and regulation of actin cytoskeleton, most of which are known contributors in MDS etiology and pathogenesis. Notably, as potential biomarkers for diagnosis of MDS, four specific genes (ABAT, FADD, DAPP1, and SMPD3) were further subjected to detailed pathway analysis. Our integrative analysis on mRNA expression, gene methylation and lncRNAs profiling facilitates further understanding of the pathogenesis of MDS, and may promote the diagnosis and novel therapeutics for this disease.
Clinical significance of apoptosis of bone marrow cells in patients with myelodysplastic syndromes

李大启,林果为,崔为发

DOI: https://doi.org/10.3969/j.issn.1002-266X.2001.05.004

2001-01-01

Abstract:Apoptosis of bone marrow mononuclear cells（BMMNC）was demonstratedusing terminal deoxytransferase（TdT）-mediated dUTP nick end labeling（TUNEL）method in 26 myelodysplastic syndromes（MDS）patients，11 megaloblastic anemia（MegA），8 paroxysmal nocturnal hemoglobinuria（PNH）and 6 Evans syndromes patients.Apoptosis was significantly increased in MDS，no difference of apoptosis was found between MegA，PNH，Evans syndromes and normal controls.Apoptosis was seen in myeloid blasts，maturing myeloid cells，nucleated erythroid cells and megakaryocyte cells in MDS patients.As MDS progressing，apoptosis gradually decreased.These results suggest that excess apoptosis is one of factors leading to ineffective hematopoiesis in MDS.MDS clinical progression may be associated with escaping from apoptosis of myelodysplastic progenitors.Therapy of anti-apoptosis could be used in early MDS patients.
Inflamma-miRs Profile in Myelodysplastic Syndrome Patients

Paola Montes,Iryna Rusanova,Elena Cornejo,Paloma García,Ana Guerra-Librero,Mª del Señor López,Tomás de Haro,Germaine Escames,Darío Acuña-Castroviejo

DOI: https://doi.org/10.3390/ijms25126784

IF: 5.6

2024-06-21

International Journal of Molecular Sciences

Abstract:Etiological factors involved in myelodysplastic syndrome (MDS) include immunologic, oxidative stress and inflammatory factors, among others, and these are targets for microRNAs (miRNs). Here, we evaluated whether some miRNs may affect tumor development comparing untreated and 5-azacitidine (5-AZA) MDS-treated patients. Peripheral blood samples were collected from 20 controls and 24 MDS patients, and selected miRNs related to redox balance and inflammation (inflamma-miRs), including miR-18a, miR-21, miR-34a and miR-146a, were isolated and measured by quantitative real-time polymerase chain reaction (qRTPCR). A differential expression profile of miRNs was detected in untreated MDS patients and the 5-AZA group. Inflammation increases miRNs and, specifically, miR-18a, miR-21 and miR-34a were significantly overexpressed in untreated MDS, compared to controls. However, we did not observe any miRN profile alteration during the progression of the disease. On the other hand, 5-AZA treatment tends to restore miRN expression levels. Relating to prognostic risk factors, high-risk MDS groups (high Revised International Prognostic Scoring System (IPSS-R), high cytogenetic risk, high molecular risk (HMR) mutations) tended to be related with higher expression levels of miR-18a and miR-34a. Higher miRN expression is correlated with lower glutathione peroxidase activity, while they are related with a higher profile of pro-inflammatory cytokines (IL-2, IL-6, IL-8, TNF-α). Although our study was limited by the low number of MDS patients included, we identified miRN deregulation involved in MDS development that could regulate redox sensors and inflammatory responses. Finally, 5-AZA treatment is related with lower miRN expression levels in MDS patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes

A F List

Abstract:The haematological diversity of myelodysplastic syndromes (MDS) mandates that therapeutic strategies for this disease be guided by an understanding of the disease biology. Insights into the pathobiology of this disease have given rise to novel treatment strategies which exploit basic biological disturbances. Myelodysplastic bone marrow progenitors from patients with low leukaemia burden display an accelerated senescence phenotype which is characterised by impaired response to trophic signals and premature apoptotic death of primitive haematopoietic progenitors. Elaboration of aptogenic cytokines such as TNF-alpha and IL-1beta may reinforce this sequence by up-regulating cellular expression of fas ligand and its cognate receptor, suppressing responsiveness to growth factor stimulation, and accelerating apoptotic cell death. Inactivation of p15 or other tumour suppressor genes antedate disease progression and the emergence of blast populations with reduced capacity for fas mediated cell death. Herein we review the current understanding of the pathobiology of MDS and promising strategies for therapeutic intervention.
Clinical And Biological Significance Of Microrna Profiling In Patients With Myeloma

sophia adamia,herve avetloiseau,samir amin,philippe moreau,stephane minvielle,steven p treon,cheng li,kenneth c anderson,nikhil c munshi

DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.8539

IF: 45.3

2009-01-01

Journal of Clinical Oncology

Abstract:8539 MicroRNA, a small endogenous RNA regulating specific expressed gene function has been implicated in normal biological processes as well as in malignant transformation. Here we have investigated the role of microRNAs in multiple myeloma (MM) biology, and their influence on prognosis and clinical outcome. We evaluated profiles of 384 microRNAs in CD138+ MM cells from 79 patients with MM, 11 cell lines and 9 healthy donors using qRT-PCR based microRNA array. We detected significant modulation of expression of 61 microRNAs in myeloma cells compared to normal plasma cells. Unsupervised hierarchical clustering of filtered matured microRNAs, identified two major groups within the MM population (groups A and group B). Group A clustered with MM cell lines, indicating more aggressive course of disease. Within B group, second degree node, group B2, clustered with normal plasma cells indicating indolent course. The unsupervised clustering of all MM samples showed consistent change in miR-146b, -140, -145, -125a, -151, -223, -155, let-7f, indicative of a role of these microRNA in myelomagenesis; while supervised analysis of samples within groups A and B identified modulated expression of different sets of miRNAs. In group A miR585 and let-7f were upregulated 8–12 fold; in group B, all differentially expressed microRNAs were downregulated (p<0.001) compared to normal plasma cells. These modulated miRNAs target critical signaling molecules such as HOX9, c-myc, Bcl-2, SHP1 and SHP2. We further analyzed the effect of microRNA on clinical outcome. We have observed significantly superior event free and overall survival of patients in group B compared to patients ingroup A (2 yr estimated EFS 79% versus 54% respectively; p=0.05; and 2 yr estimated OS 94% versus 70% respectively; p =0.017). Functional analysis by modulating miRNAs 585, 155 and let-7f showed change in levels of predicted genes with consequent biological effect on growth and apoptosis in MM cell line. Taken together, this data identifies miRNAs as critical modulators of gene expression and signaling pathways and provides potential novel targets in MM to both understand biological behavior and for therapeutic application. No significant financial relationships to disclose.
Transverse femoral arteriotomy for intraaortic balloon insertion.

D. Payne,D. H. Sewell,J. Amato,P. Faraci,H. Rheinlander,R. Cleveland

DOI: https://doi.org/10.1016/S0003-4975(10)63681-8

1978-09-01

Abstract:
MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review

Negar Habibollahzadeh,Samin Yavari,Yasin Mirazimi,Amir Hossein Aghayan,Atefeh Davoudian,Mohammad Rafiee

DOI: https://doi.org/10.1186/s12885-024-12640-9

IF: 4.638

2024-07-24

BMC Cancer

Abstract:Introduction: The therapeutic method for many malignant and non-malignant diseases is hematopoietic stem cell transplantation (HSCT), but it is not always fully successful in all patients. Indeed, HSCT can be influenced by a variety of factors. Here we reviewed the effect of microRNAs (miRs) on HSCT-related outcomes, like survival, infections, relapse, engraftment, and so on, systematically. Method: WOS, Scopus, PubMed, Google Scholar, and ProQuest databases were searched. The PRISMA guideline was performed, and 24 studies were included through quality assessment. Classified data extraction was done based on the type of disease. Results: The systematic review identified 47 miRs effective on HSCT. The role of miRs as tumor suppressors or oncogenes is reported in acute myeloblastic and lymphoblastic leukemia patients undergoing HSCT due to their effects on overall or event-free survival. Additionally, relapse after HSCT in multiple myeloma is correlated with miRs expression. Also, recovery from post-autologous HSCT cytopenia or platelet and neutrophil engraftment can be influenced by miRs. We highlighted here reports on specific miRs. Conclusion: We reported prognostic miRs for in-depth clinical management of the HSCT process and its outcomes. Also, miRs are introduced for the prevention of HSCT-related complications, and future studies are suggested to evaluate personalized medicine's utilization of miRs in therapeutic methods like HSCT in neoplasia.
MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Milad Ashrafizadeh,Hui Li Ang,Ebrahim Rahmani Moghadam,Shima Mohammadi,Vahideh Zarrin,Kiavash Hushmandi,Saeed Samarghandian,Ali Zarrabi,Masoud Najafi,Reza Mohammadinejad,Alan Prem Kumar

DOI: https://doi.org/10.3390/biom10071040

IF: 6.064

2020-07-12

Biomolecules

Abstract:Molecular signaling pathways involved in cancer have been intensively studied due to their crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding homeobox-1 (ZEB1) and -2 (ZEB2) are molecules that play vital roles in signaling pathways to ensure the survival of tumor cells, particularly through enhancing cell proliferation, promoting cell migration and invasion, and triggering drug resistance. Importantly, ZEB proteins are regulated by microRNAs (miRs). In this review, we demonstrate the impact that miRs have on cancer therapy, through their targeting of ZEB proteins. MiRs are able to act as onco-suppressor factors and inhibit the malignancy of tumor cells through ZEB1/2 down-regulation. This can lead to an inhibition of epithelial-mesenchymal transition (EMT) mechanism, therefore reducing metastasis. Additionally, miRs are able to inhibit ZEB1/2-mediated drug resistance and immunosuppression. Additionally, we explore the upstream modulators of miRs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), as these regulators can influence the inhibitory effect of miRs on ZEB proteins and cancer progression.

biochemistry & molecular biology
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Xingcheng Yang,Ling Ma,Xiaoying Zhang,Liang Huang,Jia Wei

DOI: https://doi.org/10.1186/s40164-022-00263-4

2022-03-02

Experimental Hematology and Oncology

Abstract:Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.

oncology,hematology
Promoter Methylation and Decreased Expression of Mir-124 in Myelodysplastic Syndromes

Yuesheng Meng,Qiao Xia,Jun Hu

DOI: https://doi.org/10.1182/blood.v116.21.4014.4014

IF: 20.3

2010-01-01

Blood

Abstract:Abstract Abstract 4014 The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic stem/progenitor cells. Although demethylating agents such azacytidine and decitabine have been widely used to treat MDS, the underlying molecular mechanisms remain obscure. Abnormalities of microRNAs (miRNA) have been recently associated with hematological malignancies including MDS. The miR-124 was initially demonstrated to modulate neurogenesis. It was recently shown that EVI1-induced methylation and silencing of miR-124 were present in murine MDS cells. In the retrospective study we evaluated methylation status and expression levels of miR-124 in fifteen MDS patients (subtypes included RCUD, RCMD, RAEB-1, RAEB-2 and CMML). Genomic DNA samples were modified with bisulfite and methylation at three promoter regions of miR-124 was examined with methylation-specific real time quantitative polymerase chain reaction analysis (MQPCR). In general, we observed an increased methylation levels of miR-124 in MDS patients than that in normal bone marrow (NBM, P<0.01). In accordance with this, marked depression of miR-124 was seen in six patients when compared with NBM (more than 2 times lower), as determined with quantitative reverse-transcriptive PCR assay. Moreover, there were higher degrees of promoter methylation in cases with depressed miR-124 than that in remaining cases. A negative correlation between the expression and methylation levels was statistically significant (R= -0.498, P<0.01). The change of miR-124 was not directly related to short-term clinical response or prognosis, possibly due to limited size of the sample. However, the miR-124 amount returned to basal levels in two cases (RCMD and CMML subtypes respectively) after low-dose decitabine therapy and DNA methylation of all three loci disappeared. Continued work is underway to accumulate more cases and make long-term clinical follow-up. In conclusion, this primary work suggested a possible role of the methylation-mediated silencing of miR-124 in the pathogenesis or disease progression of MDS. Disclosures: No relevant conflicts of interest to declare.

An immunohistochemical study of feline endometrial adenocarcinoma.

Evaluation of MicroRNA as Minimal Residual Disease in Leukemia: Diagnostic and Prognostic Approach: A Review

Immobilization of human mesenchymal stem cells within RGD-grafted alginate microspheres and assessment of their angiogenic potential.

MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification

Small Molecules, Big Effects: the Role of Micrornas in Regulation of Cardiomyocyte Death

miRNA Profiles in Patients with Hematological Malignancy at Different Stages of the Disease: A Preliminary Study

MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis

Integrated analysis on mRNA microarray and microRNA microarray to screen immune-related biomarkers and pathways in myelodysplastic syndrome

How do humans process and recognize speech?

Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives

Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review

An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (lncRNAs) in Myelodysplastic Syndromes

Clinical significance of apoptosis of bone marrow cells in patients with myelodysplastic syndromes

Inflamma-miRs Profile in Myelodysplastic Syndrome Patients

Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes

Clinical And Biological Significance Of Microrna Profiling In Patients With Myeloma

Transverse femoral arteriotomy for intraaortic balloon insertion.

MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review

MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Promoter Methylation and Decreased Expression of Mir-124 in Myelodysplastic Syndromes